ChEMBL v34 compound record for TIRZEPATIDE (CHEMBL4297839): max_phase 4 (approved), first_approval 2022, parenteral, GIP receptor agonist, first-in-class, black-box warning flag
Missed Dosage If you miss a scheduled dose: Do not double the next dose Follow your providers instructions for rescheduling Contact your provider or pharmacy if you are unsure how to proceed Storage Store refrigerated as directed on the pharmacy label Protect from light Do not freeze Keep out of reach of children Medication Disposal Dispose of unused or expired medication according to local medication disposal guidelines
in a 2:1:1:1:2:1:2 ratio to receive either placebo, 1 mg, 3 mg, 6 mg or 9 mg eloralintide, or an eloralintide dose escalation of 6/9 mg or 3/6/9 mg, respectively
Do not use it after the expiry date on the pack
[DOI] [PMC free article] [PubMed] [Google Scholar] [51].Mark Farrugia, Byron Baron
Julian Kessler Lead Investigator, Biomatrix Labs "The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification